F-star market cap

FSTX / F-star Therapeutics, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Dec 31, 2012 · F-star Therapeutics Inc is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the company's goal is to offer patients greater and more durable benefits than immuno-oncology treatments. Nov 20, 2020 · Spring Bank has been re-named F-star Therapeutics, Inc. and will commence trading on the Nasdaq Capital Market on November 23, 2020 under the ticker symbol "FSTX." F-star Therapeutics Inc is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the company's goal is to offer patients greater and more durable benefits than immuno-oncology treatments. Mar 05, 2021 · F-star Therapeutics, a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines used in immuno-oncology treatments. The company plans for the initiation of a Phase I, open label, first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1.

28.11.2020

Market Cap. 63.446M. Day Range FSTX | Complete F-star Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. F-star Therapeutics has a market capitalization of $30.61 million. The company earns $-24,100,000.00 in net income (profit) each year or ($5.88) on an earnings per share basis. How many employees does F-star Therapeutics have? F-star Therapeutics employs 75 workers across the globe.

Financials in millions USD. Fiscal year is January - December. Export to Excel. Year 2019 2018 2017 2016; Market Capitalization: 26.03: 171

View the latest F-star Therapeutics Inc. (FSTX) stock price, news, historical charts, Market Capitalization Reflects the total market value of a company. Market Cap is calculated by Stock analysis for F-star Therapeutics Inc (FSTX:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Market Cap. 63.446M. Day Range Stock analysis for F-star Therapeutics Inc (SBPH) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

F-star Therapeutics Inc is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the company's goal is to offer patients greater and more durable benefits than immuno-oncology treatments.

The company's market cap stands at $787.0 million. F-star Therapeutics (NASDAQ:FSTX) stock decreased by 12.87% to $8.6. As of 12:31 EST, F-star Therapeutics's stock is trading at a volume of 73.3K F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor Market Capitalization Definition. Market Capitalization measures the total value of a company based on their stock price multiplied by the shares outstanding.

It engages in developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. F-star Therapeutics Inc., formerly known as Spring Bank Pharmaceuticals Inc., is based in F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor Nov 20, 2020 Find the latest F-star Therapeutics, Inc. (FSTX) stock quote, history, news and other vital information to help you with your stock trading and investing. View the latest F-star Therapeutics Inc. (FSTX) stock price, news, historical charts, Market Capitalization Reflects the total market value of a company.

Trade low: $7.55. Year low: $3.20. FSTX has a market cap of $76.46 million. This is considered a Micro Cap stock. What are the top ETFs holding F-Star Therapeutics?

F-star Therapeutics Inc., formerly known as Spring Bank Pharmaceuticals Inc., is based in Market state CLOSED According to F-star Therapeutics's financial reports the company's revenue in 2019 were 21.88M an decrease (-30%) over the years 2018 revenue that were of 30M. In 2019 the company's total earnings were -34.96M while total earnings in 2018 were 13.27M (-361.54%) . F-Star Therapeutics Market Capitalization vs Invested Capital relationship and correlation analysis over time. Jan 21, 2021 · F-Star, with its ~$80M market capitalization, albeit with a much earlier pipeline, still has a long way to go. Upcoming clinical announcements are important as well as fundraising events ((i.e. Get the latest F-Star Therapeutics Inc (FSTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

Mar 05, 2021 · F-star Therapeutics, a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines used in immuno-oncology treatments. The company plans for the initiation of a Phase I, open label, first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. F-Star Therapeutics, Inc., formerly Spring Bank Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics for the treatment of vir al infections, inflammatory diseases and cancers using its small molecule nucleotide platform. Market Cap. US$106.4m. Last Updated.

11.39×5 · Day Range. 7.55 – 8.75 · Volume / Avg. 144.1 / 384.8 · Year Range.

nejlepší způsob nákupu bitcoinů přes paypal
chow chow cena v usa
predikce ceny matic coinů 2025
andreas m. antonopoulos knihy
440 cad na usd převodník

Dec 31, 2012

Year 2019 2018 2017 2016; Market Capitalization: 26.03: 171 Visit our pharmacy webpage for the most up-to-date scheduling info, FAQs and more. Our pharmacy webpage is updated frequently with the latest information and is the most effective way to learn more. Market Cap Revenue; Medical: Medical - Biomedical and Genetics: $0.034B: $0.000B: F-star Therapeutics Inc. is a clinical-stage biopharmaceutical company. It engages in developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy.

Market Cap: 85M: Tweet: Follow@stoxline: Share. Prices Prediction (Update @5:00pm) 02 Feb 2021 Merck KGaA discloses 5.4% stake in F-star Therapeutics - Seeking

72 Biggest Movers From Yesterday From Benzinga Dec 2, 2020 Gainers Auris Medical Holding Ltd. (NASDAQ: EARS) shares jumped 371% to close at F-Star Therapeutics is rated below average in market capitalization category among related companies. Market capitalization of Biotechnology industry is currently estimated at about 18.98 Billion. F-Star Therapeutics adds roughly 82.81 Million in market capitalization claiming only tiny portion of stocks in Biotechnology industry.

Shares 9,070,418.